Inimmune to Showcase Pipeline Advances at World Vaccine Congress 2026
Missoula, MT — March 29, 2026 — Inimmune, a biotechnology company advancing next-generation vaccine adjuvants and immunotherapies, today announced that its leadership team will present new data and insights at the World Vaccine Congress (WVC) in Washington, DC, from March 30 to April 2, 2026. CEO David Burkhart, Ph.D., will chair the “Vaccine Technology Workshop” […]
Inimmune Completes Enrollment and Doses First Patient in Phase 2 Chamber Trial of INI-2004 for Allergic Rhinitis
INI-2004 advances as a rapid, disease-modifying immunotherapy for allergic rhinitis with platform potential across all allergic diseases; topline data expected June 2026 Missoula, MT — March 11, 2026 — Inimmune Corporation, a clinical-stage biotechnology company developing novel immunotherapies for allergic diseases, today announced the completion of enrollment and dosing of the first patient in its […]
Inimmune Strengthens Leadership Team Ahead of Phase 2 INI-2004 Allergic Rhinitis Data Readout
Missoula, MT – March 5, 2026 – Inimmune Corporation, a clinical-stage biotechnology company developing next-generation immunotherapies, today announced the appointments of Ferdinand Massari, M.D., as Chief Medical Officer (CMO), and Ryan McMillian as Head of Financial Strategy. The appointments strengthen the leadership team as Inimmune advances its lead allergic rhinitis program, INI-2004, toward key milestones […]
